Advanced BioScience Labs — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Advanced BioScience Labs (ABL) is a long-established, private biotech services firm operating as a CDMO/CRO with a core focus on viral vectors and vaccines. The company provides a full suite of capabilities, including process development, GMP manufacturing, analytical testing, and immunology assay services, primarily for client-sponsored therapeutics in infectious disease and oncology. With recent recognition as a 'Best Contract Manufacturing Organization' and a demonstrated European presence in France, ABL is positioned as a specialized partner for complex biologic and advanced therapy development. Its business model is service-based, generating revenue through client contracts.

Infectious DiseaseOncology

Technology Platform

Integrated CDMO/CRO platform specializing in viral vector biomanufacturing (using single-use bioreactor systems) and immunobiology (custom assay development for immunogenicity and biomarker analysis).

Opportunities

Strong market demand for viral vector manufacturing capacity and vaccine development services, driven by growth in gene therapy and ongoing infectious disease threats.

Geographic expansion in Europe provides access to new clients and funding ecosystems.

Industry recognition enhances credibility for winning major contracts.

Risk Factors

Revenue dependency on the success and financial health of client biotechs, which are often high-risk.

Intense competition from larger CDMOs and operational risks associated with complex GMP manufacturing.

Requires continuous capital investment to maintain technological edge and capacity.

Competitive Landscape

ABL competes in a crowded CDMO market against large global players (e.g., Lonza, Catalent, Thermo Fisher) and specialized viral vector CDMOs. Its differentiation lies in its long-standing history, integrated immunology services, and specific focus on challenging viral products. The award-winning reputation in vaccines is a key competitive asset.

More companies in Cell & Gene Therapy →More companies in United States →